Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Publié dansEuropean journal of nuclear medicine and molecular imaging, vol. 48, no. 7, p. 2086-2096
Date de publication2021-07
Date de mise en ligne2021-03-15
Résumé
Mots-clés
- Alzheimer’s disease
- Biomarker-based diagnosis
- PBB3
- Strategic roadmap
- THK
- Tau PET
- Alzheimer Disease / diagnostic imaging
- Biomarkers
- Brain / metabolism
- Humans
- Ligands
- Positron-Emission Tomography
- Tau Proteins / metabolism
Citation (format ISO)
CHIOTIS, Konstantinos et al. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. In: European journal of nuclear medicine and molecular imaging, 2021, vol. 48, n° 7, p. 2086–2096. doi: 10.1007/s00259-021-05277-4
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:160679
- DOI : 10.1007/s00259-021-05277-4
- PMID : 33723628
- PMCID : PMC8175292
ISSN du journal1619-7070